# Leptin to Treat Lipodystrophy

> **NCT00025883** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 103 (actual)

## Conditions studied

- Lipodystrophy

## Interventions

- **DRUG:** Metreleptin

## Key facts

- **NCT ID:** NCT00025883
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2016-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025883, "Leptin to Treat Lipodystrophy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00025883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*